 Among all the incidence of cancers, lung cancer is one of the top ranked cancer with the highest mortality rate in 2006-2010. Novel targeted therapy -Gefitinib has been shown to improve progression free survival (PFS) and a substantially better adverse-effects profile than conventional chemotherapy in NSCLC. 3, 4  To determine the trend of use of targeted therapy in National Cancer Centre Singapore (NCCS) from 2007-2011.
 To evaluates the treatment response of Gefitinib in NSCLC patients.
 To conduct an economic evaluation of Gefitinib for advanced non-small cell lung cancer (NSCLC) patients without prior chemotherapy.
Study Design » Retrospective study conducted at outpatient clinic in NCCS. Probabilities » Probability of staying in each health state or transition to various health states for Gefitinib were derived from 124 patients in the study cohort. The probabilities for CP were determined by using hazard ratio (HR) from IPASS trial. Assumption made: Survival curves were exponential and the rates were constant over time.
Resources utilization » Medical resources consumed were collected from Gefitinib study cohort. Whereas, expert opinions and IPASS trial were used for CP.
Costs » Costs were based on the unit selling price listed in NCCS.
Utilities » Health states, adverse events and administration mode were associated with utilities. All utilities were obtained from published literatures (Evidence Review group report, 2006 and Nafees, 2008) Discounting » Both costs and utilities were discounted at an annual rate of 3%.
Perspective » Analyzed from the perspective of health care purchaser (Ministry of Health), hence only direct medical costs were considered.
Trends of use:
 Total number of patients receiving targeted therapy in NCCS increased significantly from 585 patients in 2007 to 1119 patients in 2011 (Fig. 2)  Fig. 3 
Conclusion
 Top three targeted therapy with high utilization and consumption costs in NCCS were Trastuzumab, Gefitinib and Bevacizumab.
 If 1-3 times of gross domestic product (GDP) range is an acceptable threshold in Singapore, Gefitinib can be considered cost-effective in this study when compared to conventional chemotherapy as a first line treatment for NSCLC.
